Arabic Arabic English English French French German German
dark

Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has signed an agreement to acquire exclusive U.S. commercialization rights to Simbrinza®(brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% from Novartis. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Canon Medical Expands AI-Based Image Reconstruction Technology to Body Applications on Galan 3T MR System

Next Post

Arch Capital Group unveils Q1 financials

Related Posts
Total
0
Share